PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial

ПЭГ 3350 (Транзипег) по сравнению с лактулозой в лечении функционального запора у детей: двойное слепое рандомизированное контролируемое многоцентровое исследование
Wieger Voskuijl, F de Lorijn, W Verwijs, P Hogeman, J Heijmans, W Mäkel, J Taminiau, M Benninga
2004-10-11

PEG 3350childhood functional constipationencopresislactuloserandomized controlled trial
BACKGROUND: Recently, polyethylene glycol (PEG 3350) has been suggested as a good alternative laxative to lactulose as a treatment option in paediatric constipation. However, no large randomised controlled trials exist evaluating the efficacy of either laxative. AIMS: To compare PEG 3350 (Transipeg: polyethylene glycol with electrolytes) with lactulose in paediatric constipation and evaluate clinical efficacy/side effects. PATIENTS: One hundred patients (aged 6 months-15 years) with paediatric constipation were included in an eight week double blinded, randomised, controlled trial. METHODS: After faecal disimpaction, patients <6 years of age received PEG 3350 (2.95 g/sachet) or lactulose (6 g/sachet) while children > or =6 years started with 2 sachets/day. Primary outcome measures were: defecation and encopresis frequency/week and successful treatment after eight weeks. Success was defined as a defecation frequency > or =3/week and encopresis < or =1 every two weeks. Secondary outcome measures were side effects after eight weeks of treatment. RESULTS: A total of 91 patients (49 male) completed the study. A significant increase in defecation frequency (PEG 3350: 3 pre v 7 post treatment/week; lactulose: 3 pre v 6 post/week) and a significant decrease in encopresis frequency (PEG 3350: 10 pre v 3 post/week; lactulose: 8 pre v 3 post/week) was found in both groups (NS). However, success was significantly higher in the PEG group (56%) compared with the lactulose group (29%). PEG 3350 patients reported less abdominal pain, straining, and pain at defecation than children using lactulose. However, bad taste was reported significantly more often in the PEG group. CONCLUSIONS: PEG 3350 (0.26 (0.11) g/kg), compared with lactulose (0.66 (0.32) g/kg), provided a higher success rate with fewer side effects. PEG 3350 should be the laxative of first choice in childhood constipation.
1
At mean doses of 0.26 g/kg for PEG 3350 and 0.66 g/kg for lactulose, PEG 3350 demonstrated greater overall efficacy with fewer side effects.
2
In an eight-week double-blind randomized trial, both PEG 3350 and lactulose significantly increased defecation frequency and reduced encopresis in children with constipation.
3
PEG 3350 caused less abdominal pain, straining, and painful defecation than lactulose, but bad taste was reported more frequently.
4
The findings support PEG 3350 as the preferred first-choice laxative for childhood functional constipation.
5
Treatment success was significantly higher with PEG 3350 than lactulose, occurring in 56% versus 29% of patients, respectively.

children aged 6 months–15 years with functional constipation treated with PEG 3350 or lactulose

comparative clinical efficacy, treatment success, and side-effect profiles of PEG 3350 versus lactulose over eight weeks

Publication Details
Publication Date
2004-10-11
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Wieger Voskuijl
F de Lorijn
W Verwijs
P Hogeman
J Heijmans
W Mäkel
J Taminiau
M Benninga
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%